leadf
logo-loader
viewEmerald Bioscience Inc.

Emerald Bioscience gearing up for first in-human clinical trial in Australia to treat glaucoma

Emerald Bioscience Inc (OTCMKTS:EMBI) CEO Brian Murphy spoke with Proactive’s Steve Darling at the 12th annual LD Micro Conference in Bel Air, California, about the medical cannabis company’s proprietary suite of technologies, including its lead product candidate that could reduce intraocular pressure.

Emerald Bioscience gearing up for first in-human clinical trial in Australia. 

Quick facts: Emerald Bioscience Inc.

Price: 0.0365 USD

OTCQB:EMBI
Market: OTCQB
Market Cap: $8.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ipsidy joins Fast Identity Online Alliance, a consumer protection-focused...

Ipsidy Inc (OTCQB:IDTY) CEO Phil Kumnick tells Proactive the technology group has joined the Fast Identity Online (FIDO) Alliance, a coalition formed to address the problems users face in creating and remembering usernames and passwords with biometric other authentication solutions. Kumnick says...

3 hours, 16 minutes ago

2 min read